aaacchhhhh,,,DMcC is probably a passive observer around negotiations with any major if there are advanced negotiations in the present. I would suggest detailed negotiations are not actually being performed by DMcC at all cuz it would be foolish to assume the opposide side of the table sit inexperienced senior pharma negotiators. David and Goliath so to speak. Dont bring a sandwich to a picnic!!!

There is no urgency in anything we have been given insight to as of late. A year of stagnation past and another year possibly ahead of us. However the salaries dont stagnate. A good point was made by RVXOT in that DMcC has more than likely taken home more cash than the cost of any of our major trials cost. That should resinate in ones mind a bit. And for those who have started thier own business out there will certainly understand that if you keep your company healthy, it will in turn keep you healthy.

Eastern and Hepa have been sort of complacent with their investment here in some respects,,,even allowing our IP to be exposed over and over. Perhaps that has been due to internal politics, maybe. However DMcC knows he has to have these two major insiders supporting any attempt to advance the science. Our share price is not important to Dart or Li Li but market share is or will be. A low share price only benefits these types when it comes to development of anything. There has been ample time and most likely opportunity to have partnered on one of the other molecules years back but that seems to have been off the table since more than one major insider took their position,,,DMcC mentioned Dart was willing to take 208 to the finish line,,possibly just a posturing comment,,but none the less made....no matter, it would seem he has left his man purse at home at this point!!....all,,,,,Just an opinion.